Hypoxanthine production by ischemic heart demonstrated by high pressure liquid chromatography of blood purine nucleosides and oxypurines

F. Harmsen *, J.W. de Jong and P.W. Serruys

Cardiochemical and Catheterization Laboratories, Thoraxcenter, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam (The Netherlands)

(Received November 25th, 1980)

Summary

An isocratic high pressure liquid chromatographic system was developed for the estimation of purine nucleosides and oxypurines in blood. Use was made of a reversed-phase column. Nucleotides derived from erythrocytes affected the separation; these compounds were removed with A12O3. The recovery of the whole clean-up procedure exceeded 75%, and the lower detection limit of the assay for blood metabolites was 0.1 μmol/l. In 6 healthy volunteers, non-resting, the following blood concentrations (mean values ± S.D. in μmol/l) were observed: adenosine (< 0.1), inosine (0.2 ± 0.1), hypoxanthine (2.2 ± 1.3) and xanthine (0.2 ± 0.1). In plasma and serum the total amount of these compounds was 1.9 and 5.4 times higher, respectively, presumably due to nucleotide breakdown during blood processing. The myocardial arterial-venous differences of blood purine nucleosides, oxypurines and lactate were subsequently measured in blood samples from 13 patients with angiographically documented ischemic heart disease, undergoing an atrial pacing stress test. No significant release of adenosine, inosine and xanthine by the heart was detectable in this study. The myocardial arterial-venous difference of lactate changed from 0.01 ± 0.03 mmol/l (mean ± SEM) at rest, to −0.10 ± 0.04 mmol/l during pacing (p < 0.002). Relatively larger changes were observed for hypoxanthine: pacing increased the arterial-venous difference from −0.01 ± 0.05 to −0.51 ± 0.17 μmol/l (p < 0.02). We conclude that the high pressure liquid chromatographic assay of blood hypoxanthine is a useful tool in the diagnosis of ischemic heart disease.

* To whom correspondence should be addressed.
Introduction

During and after hypoxia or ischemia, there is in the heart, as well as in other muscles, excessive ATP breakdown. This degradation of ATP causes an efflux of breakdown products, which are able to pass through the cell membrane, and are released into the blood. The purine derivatives adenosine, inosine and hypoxanthine are thought to be markers for ischemia (for a review, see ref. [1]). Because of high activities of adenosine deaminase (EC 3.5.4.4; ADA) and nucleoside phosphorylase (EC 2.4.2.1; NP), and low or non-detectable amounts of xanthine oxidase (EC 1.2.3.2; XO) in the heart and blood, hypoxanthine seems very promising as marker for myocardial ischemia [2,3]. Enzymatic purine determinations [4,5] are time-consuming and do not differentiate between hypoxanthine and xanthine. Recently high pressure liquid chromatography (HPLC) came into use for the determination of nucleosides and purine bases in urine, plasma and serum [6–8]. We have developed a method to determine these compounds in blood, and have compared the levels of adenosine, inosine, hypoxanthine and xanthine in blood, plasma and serum. With the assay we demonstrated the myocardial release of hypoxanthine in patients with angiographically documented ischemic heart disease, undergoing an atrial pacing stress test.

Materials and methods

Enzymes (XO, 13 U/ml; NP, 10 U/ml; ADA, 140 U/ml) were purchased from Boehringer-Mannheim, F.R.G.; CH₂OH (Uvasol), NH₄H₂PO₄, KOH, K₂CO₃, adenosine, hypoxanthine and uridine from Merck (Darmstadt, F.R.G.). Uric acid was supplied by Sigma (Saint Louis, MO, U.S.A.), and the other standards by Koch-Light (Colnbrook, Bucks., U.K.). Al₂O₃ came from Desaga, Heidelberg, F.R.G. [U-¹⁴C]nucleosides and oxypurines were obtained from The Radiochemical Centre (Amersham, Bucks., U.K.; spec. act. 50–60 Ci/mol). HClO₄ was supplied by Merck, and used as a 1.3 mol/l dilution. Water was purified with the Milli-Ro4/Milli-Q system (Millipore Co., Bedford, MA, U.S.A.).

Blood sample treatment

Blood (2.0 ml) was deproteinized immediately with an equal volume of HClO₄ as described by Remme et al. [2]. Plasma was prepared by adding 3 ml blood to a heparinized tube and immediate centrifugation for 15 min at 3000 × g (4°C). Serum was prepared from 3 ml blood which had been allowed to clot at room temperature for 30 min and subsequent centrifugation. Plasma and serum were also deproteinized with equal volumes of HClO₄. After centrifugation, the supernatant fluids were stored at −20°C. The acid extracts were brought to pH 5–7 at 0°C with an automatic titration device (Radiometer, Copenhagen) using 150–200 μl 6 mol/l KOH + 1 mol/l K₂CO₃. KClO₄ was spun down for 10 min at 12000 × g at 4°C. For plasma and serum 200 μl of these extracts were directly injected onto the HPLC column. For whole blood extracts, removal of nucleotides appeared to be necessary. We used the method of Chatterjee et al. [9], with some minor differences. We applied
1.5 ml of the deproteinized, neutralized blood sample onto a pre-washed column of
Al₂O₃ (0.6 g) in a Pasteur pipette, and eluted it with 5.0 ml 10 mmol/l Tris/HCl,
pH 7.4. For faster elution, a vacuum was applied; with a 1225 sampling manifold
(Millipore Co.) 12 samples were treated at the same time. With standards (about 10
µmol/l oxypurines and nucleosides, and about 5 mmol/l nucleotides), we found
recoveries exceeding 90%, whereas the nucleotides were fully retained. These values
are in close agreement with values in the literature [9].

Recovery studies for blood treatment
To carry out recovery studies, it is necessary to inactivate first the purine
metabolizing enzymes in the blood. We achieved this by rapid mixing of blood with
cold HClO₄. This procedure is comparable to the determination of recoveries after
inactivation of enzymes by freeze-clamping heart tissue, or removal of cells from
blood, and subsequent addition of standards [4,5,7,8,10–12]. If radioactive standards
were used 10 µl ¹⁴C-labelled hypoxanthine, xanthine, inosine or adenosine were
mixed with 10 ml HClO₄. For the determination of radioactivity 50 µl aliquots were
mixed with 10 ml Insta-gel (Packard Instr. Co., Downers Grove, IL, U.S.A.) and
counted with a Packard Tricarb 2650 liquid scintillation counter.

High pressure liquid chromatography
A Varian 8520 high pressure liquid chromatograph (Varian, Palo Alto, CA,
U.S.A.) was used with a pneumatic sampling device (Valco Instr. Co., Houston, TX,
U.S.A.), an autosampler (Varian), a Model 440 fixed wavelength UV-detector
(Waters Assoc., Milford, MA, U.S.A.) and a chromatographic data system C-111
(Varian). A 4 mm I.D. × 30 cm prepacked µBondapak/C₁₈ column (Waters Assoc.)
was used in these studies. The packing material has an average particle size of 10 µm
and consists of porous silica to which a monolayer of octadecyltrichlorosilane is
cchemically bound. Chromatographic conditions were adapted from earlier work [13].
200 µl samples were eluted from this column with 10 mmol/l NH₄H₂PO₄/CH₃OH
(10:1, v/v), pH 5.50. The flow rate was 60 ml/h (p = 80 bar).

Lactate assay
Lactate was determined in acid supernatants in duplicate with an AutoAnalyzer
II (Technicon, Tarrytown, NY, U.S.A.) as described by Apstein et al. [14].

Statistical analysis
Statistical analysis in Table II was performed with a two-group comparison test
based on Student's $t$ distribution, and those in Table III and Fig. 5 by Student's
paired $t$ test. $p$-values < 0.05 (two-sided) were considered significant.

Results

HPLC
Fig. 1 represents the separation of several nucleosides and purine bases. The lower
detection limit with a 200 µl sample loop is 0.01 µmol/l; the method is linear up to
200 μmol/l (Fig. 2). The standard deviation at the 10, 1 and 0.1 μmol/l level is < 0.12%, < 5% and < 9%, respectively (n = 9). Identification of the compounds in pre-purified blood samples was achieved by retention times (Fig. 3a), co-chromatography of standards (Fig. 3b) and enzyme shifts (Fig. 3c), as described by Hartwick et al. [7]. The clean-up procedure of the blood samples causes a 9-fold dilution, which increased the lower detection limit in blood to 0.1 μmol/l.

![Retention time (min)](image)

Fig. 1. Isocratic HPLC separation of nucleosides and purine bases (2–4 μmol/l). Column: μBondapak C18 (4×300 mm). Buffer: 10 mmol/l NH₄H₂PO₄/CH₃OH (10:1, v/v), pH 5.50. Flow rate: 60 ml/h. Injected sample volume: 200 μl. 1. uric acid; 2. uracil; 3. uridine; H, hypoxanthine; X, xanthine; 4. xanthosine; 1, inosine; 5, guanosine; 6, adenine; A, adenosine.

**Recoveries**

With radioactive standards the recoveries for the whole clean-up procedure exceeded 75% (Table I). With non-radioactive standards, assayed by HPLC, we found comparable recoveries in the concentration range of our interest (Fig. 4).
Fig. 2. Calibration curves for HPLC of hypoxanthine (○—○) \( y = 2.16x - 0.09, r = 1.000 \); xanthine (●—●) \( y = 0.73x + 0.01, r = 0.999 \); inosine (■—■) \( y = 1.59x + 0.02, r = 1.000 \); adenosine (□—□) \( y = 2.23x - 0.05, r = 0.999 \).

**Purine derivatives in blood, plasma and serum**

Six healthy non-fasting, non-resting volunteers donated venous blood. In their blood, plasma and serum, hypoxanthine, xanthine, inosine and adenosine were

**TABLE I**

RECOVERY OF PURINE NUCLEOSIDES AND OXYPURINES DURING SAMPLE PREPARATION

(Data represent mean values of 6 experiments± S.E.M.)

<table>
<thead>
<tr>
<th>Clean-up stage</th>
<th>Adenosine</th>
<th>Inosine</th>
<th>Hypoxanthine</th>
<th>Xanthine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acidified human blood (100%)</td>
<td>50000</td>
<td>330000</td>
<td>230000</td>
<td>44000</td>
</tr>
<tr>
<td>Acid supernatant</td>
<td>96 ± 3</td>
<td>106 ± 1</td>
<td>101 ± 1</td>
<td>93 ± 4</td>
</tr>
<tr>
<td>Neutralized extract</td>
<td>88 ± 2</td>
<td>101 ± 2</td>
<td>92 ± 2</td>
<td>99 ± 4</td>
</tr>
<tr>
<td>Alumina eluate</td>
<td>79 ± 2</td>
<td>91 ± 4</td>
<td>86 ± 1</td>
<td>76 ± 6</td>
</tr>
</tbody>
</table>
Fig. 3 (a, b and c). Chromatogram of blood from a normal donor. (a) Blood was deproteinized and purified as described under "Materials and methods". Conditions, see Fig. 1. (The upper panel represents the same chromatogram with a 4 times lower detector sensitivity.) H, hypoxanthine; X, xanthine; I, inosine; A, adenosine.

TABLE II

CONCENTRATION OF ADENOSINE, INOSINE AND (HYPO)XANTHINE IN HUMAN BLOOD, PLASMA AND SERUM

(Data represent mean values in μmol/l of 5–6 volunteers ± S.D.)

<table>
<thead>
<tr>
<th>Preparation</th>
<th>Adenosine (μmol/l)</th>
<th>Inosine (μmol/l)</th>
<th>Hypoxanthine (μmol/l)</th>
<th>Xanthine (μmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td>&lt;0.1</td>
<td>0.2 ± 0.1</td>
<td>2.2 ± 1.3</td>
<td>0.2 ± 0.1</td>
</tr>
<tr>
<td>Plasma</td>
<td>&lt;0.1</td>
<td>0.2 ± 0.2</td>
<td>3.6 ± 0.8</td>
<td>1.1 ± 0.7  *</td>
</tr>
<tr>
<td>Serum</td>
<td>0.9 ± 0.2 *•</td>
<td>1.0 ± 0.4 *•</td>
<td>5.6 ± 1.9  *</td>
<td>6.6 ± 2.1 *•</td>
</tr>
</tbody>
</table>

* p<0.05 vs. blood, ▲ p<0.05 vs. plasma.
determined. The results are listed in Table II. As can be seen plasma shows 1.6 times higher levels of hypoxanthine and 5.5 times higher levels of xanthine than blood. Serum has significantly higher values of the AMP-catabolites. Here the values are 2.5 times (for hypoxanthine) to 33 times (for xanthine) higher, compared to blood.

**Determination of blood purine nucleosides, oxypurines and lactate of patients with ischemic heart disease**

Thirteen patients with angina pectoris were catheterized as described by Remme et al. [2]. The patients were fasted overnight and 36 h before catheterization all medication was stopped. Before catheterization 50000 IE of heparin were infused. The diagnosis, ischemic heart disease, was established by angiography (obstruction of at least one coronary artery \( > 50\% \)). Before angiography an atrial pacing stress
Fig. 3(c). Chromatogram as in (a), after 30 min incubation with XO, NP and ADA, 5 μl each.

test was performed. During a control period, maximal pacing, and 5 and 20 min after pacing, arterial and coronary sinus blood samples were taken. At rest no significant myocardial arterial-venous hypoxanthine or lactate difference was seen (Fig. 5). During maximal pacing, a rise in coronary sinus hypoxanthine (from 0.83 to 1.43 μmol/l, p < 0.01) and lactate (from 0.87 to 0.98 mmol/l, p < 0.005) was observed, which fell off after pacing. The arterial levels of these compounds remained constant. The myocardial arterial-venous difference of hypoxanthine changed from −0.01 μmol/l at rest to −0.51 μmol/l (p < 0.02) during pacing (Table III). We showed in earlier work [2,15] that patients with anginal pain, but with patent coronary arteries (< 50% obstruction), did not produce myocardial hypoxanthine. Relatively smaller changes were observed for lactate: pacing in-
Fig. 4. Recoveries determined by HPLC. Standards were dissolved in HClO₄, before blood was added. Hypoxanthine: \( O - O \) \( y = 0.72x + 0.77, r = 0.997 \); xanthine: \( O - O \) \( y = 0.68x + 0.01, r = 0.999 \); inosine: \( O - O \) \( y = 0.77x - 0.03, r = 0.993 \); adenosine: \( O - O \) \( y = 0.77x + 0.20, r = 0.995 \). For conditions, see legends to Figs. 1 and 3.

Fig. 5. Arterial \( O - O \) and coronary sinus \( O - O \) hypoxanthine and lactate levels during an atrial pacing stress test of 13 patients with ischemic heart disease. \( C_1 \), control period; \( P_1 \), maximal pacing; \( C_2 \) and \( C_3 \), 5 and 20 min after maximal pacing, respectively. Mean values are given with 1 S.E.M. \( * p < 0.05 \) vs. arterial levels.

TABLE III

**MYOCARDIAL ARTERIAL-VENOUS DIFFERENCES AND EXTRACTION VALUES OF HYPOXANTHINE AND LACTATE DURING AN ATRIAL PACING STRESS TEST OF PATIENTS WITH ISCHEMIC HEART DISEASE**

The extraction value is defined as the arterial concentration minus coronary sinus concentration divided by the arterial concentration, times 100%. Mean values are given ± S.E.M. \( n = 13 \).

<table>
<thead>
<tr>
<th>Heart rate (beats/min)</th>
<th>Hypoxanthine</th>
<th>Lactate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A − CS (μmol/l)</td>
<td>Extraction (%)</td>
</tr>
<tr>
<td>( C_1 ) 79 ± 4</td>
<td>−0.01 ± 0.05</td>
<td>−6 ± 6</td>
</tr>
<tr>
<td>( P_1 ) 144 ± 4 *</td>
<td>−0.51 ± 0.17 *</td>
<td>−68 ± 18 *</td>
</tr>
<tr>
<td>( C_2 ) 78 ± 4</td>
<td>−0.33 ± 0.14 *</td>
<td>−49 ± 14 *</td>
</tr>
<tr>
<td>( C_3 ) 80 ± 4</td>
<td>−0.15 ± 0.08</td>
<td>−35 ± 14</td>
</tr>
</tbody>
</table>

\* \( p < 0.05 \) vs. \( C_1 \).

A − CS, arterial-venous difference; \( C_1 \), control period; \( P_1 \), maximum pacing; \( C_2 \), 5 min after pacing; \( C_3 \), 20 min after pacing.
creased the arterial-venous difference from 0.01 to $-0.10 \text{ mmol/l}$ ($p < 0.002$, see Table III). Significant production of lactate, calculated either as arterial-venous difference or extraction, only took place during maximal pacing, but significant hypoxanthine release was also present 5 min after pacing was stopped (Table III). The coronary sinus levels of adenosine, inosine and xanthine during the control period were $0.17 \pm 0.04$, $0.53 \pm 0.11$ and $0.20 \pm 0.14 \mu\text{mol/l}$, respectively. No significant arterial-venous differences were observed throughout the test.

**Discussion**

Hypoxanthine, xanthine, inosine and adenosine levels in human blood (or plasma or serum) have been measured in normal adults [7–11,16], patients with gout [17], immunological disorders [18], ischemic heart disease [2,3,19,20], pregnant women [21], and children [21]. The values reported show considerable variation, which could be caused by:

1. Differences in assay methods. The enzymatic determination of hypoxanthine, for instance, does not differentiate between hypoxanthine and xanthine.

2. As we have shown in Table II, large differences occur in the levels of these compounds when these are measured in blood, plasma or serum from the same person. These differences can be explained by the enzymatic degradation of ATP, derived from blood cells, and ADP, released from platelets during clotting [7,8]. Furthermore, xanthine, as the end-product of guanine nucleotide catabolism, can be expected to occur in higher concentrations in plasma and serum than in blood. For instance, blood xanthosine, guanosine and guanine are rapidly converted to xanthine [22]. For this reason instant inactivation by acid seems indicated, when one wants to determine the nucleoside and oxypurine concentration in the blood.

3. Physical activity also influences the levels of these AMP catabolites in blood. Sutton et al. [23] showed that the plasma levels of oxypurines are twice as high during and after physical training compared with control levels. Although they did not measure inosine levels in the plasma, urinary inosine during exercise is elevated tenfold, possibly indicating increased inosine levels in the blood. Therefore, if one wants to measure normal values, it is also important to define the physical state of the group under study.

We feel that measuring myocardial arterial-venous differences of blood hypoxanthine levels could give insight into the metabolic state of the heart; the method described here makes it possible to measure a number of purine metabolites in blood. The observations on the patients undergoing an atrial pacing stress test indicate that hypoxanthine is a more sensitive parameter for myocardial ischemia than adenosine, inosine, xanthine or lactate, because hypoxanthine release is more pronounced and of a longer duration than that of the other compounds.

**Acknowledgements**

We thank Mr. W.A.P. Breeman, Mr. J.A.J. Hegge and our colleagues at the Catheterization Laboratory for their cooperation in part of the study and Elisabeth
Keijzer and P.Ph. de Tombe for their technical assistance. Dr. J.W. de Jong was an established investigator of the Dutch Heart Foundation when this study was carried out.

References


19 Fox, A.C., Reed, G.E., Meilman, H. and Silk, B.B. (1979) Release of nucleosides from canine and human hearts as an index of prior ischemia. Am. J. Cardiol. 43, 52–58